1. Lupsor-Platon M, Stefanescu H, Muresan D, et al. Noninvasive assessment of liver steatosis using ultrasound methods. Med Ultrason 2014;16:236–245.
2. Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 2012;36:13–20.
3. Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 2007;189:W320–W323.
5. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol 2017;67:862–873.
6. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62:S47–S64.
7. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015;62:1148–1155.
10. Serfaty L. Management of patients with non-alcoholic steatohepatitis (NASH) in real life. Liver Int 2018;38 Suppl 1:52–55.
11. Iacob S, Ester C, Lita M, Ratziu V, Gheorghe L. Real-life perception and practice patterns of NAFLD/NASH in Romania: results of a survey completed by 102 board-certified gastroenterologists. J Gastrointestin Liver Dis 2016;25:183–189.
12. Cengiz M, Senturk S, Cetin B, Bayrak AH, Bilek SU. Sonographic assessment of fatty liver: intraobserver and interobserver variability. Int J Clin Exp Med 2014;7:5453–5460.
14. Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007;102:2708–2715.
15. Mottin CC, Moretto M, Padoin AV, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004;14:635–637.
16. de Ledinghen V, Vergniol J, Capdepont M, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol 2014;60:1026–1031.
17. Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010;36:1825–1835.
19. Chon YE, Jung KS, Kim SU, et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int 2014;34:102–109.
21. Carvalhana S, Leitao J, Alves AC, Bourbon M, Cortez-Pinto H. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. Liver Int 2014;34:e111.
22. Myers RP, Pollett A, Kirsch R, et al. Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012;32:902–910.
24. Perez NE, Siddiqui FA, Mutchnick MG, et al. Ultrasound diagnosis of fatty liver in patients with chronic liver disease: a retrospective observational study. J Clin Gastroenterol 2007;41:624–629.
31. Huh JH, Kim KJ, Kim SU, et al. Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status. Metabolism 2017;66:23–31.
33. Ferraioli G, Tinelli C, De Silvestri A, et al. The clinical value of controlled attenuation parameter for the noninvasive assessment of liver steatosis. Liver Int 2016;36:1860–1866.
34. de Ledinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012;32:911–918.